Saylor, Keith

Bullies, Victims, and Bully/Victims: Distinct Groups of At-Risk Youth

Haynie, D. L., Nansel, T., Eitel, P., Crump, A. D., Saylor, K., Yu, K., & Simons-Morton, B. (2001) · The Journal of Early Adolescence

Bullying, Victimization, and AggressionWorkplace Violence and Bullying

Cited by 897

Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 599

Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial

Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics

Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

Cited by 464

Quality of Life Assessment in Adult Patients With Attention-deficit/Hyperactivity Disorder Treated With Atomoxetine

Adler, L. A., Sutton, V. K., Moore, R. J., Dietrich, A. P., Reimherr, F. W., Sangal, R. B., Saylor, K. E., Secnik, K., Kelsey, D. K., & Allen, A. J. (2006) · Journal of Clinical Psychopharmacology

Attention Deficit Hyperactivity DisorderHealth Systems, Economic Evaluations, Quality of Life

Cited by 79

Effects of Atomoxetine on Growth in Children with Attention-Deficit/Hyperactivity Disorder Following up to Five Years of Treatment

Spencer, T. J., Kratochvil, C. J., Sangal, R. B., Saylor, K. E., Bailey, C. E., Dunn, D. W., Geller, D. A., Casat, C. D., Lipetz, R. S., Jain, R., et al. (2007) · Journal of Child and Adolescent Psychopharmacology

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 75

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 62

Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD

Brown, T. E., Holdnack, J., Saylor, K., Adler, L., Spencer, T., Williams, D. W., Padival, A. K., Schuh, K., Trzepacz, P. T., & Kelsey, D. (2011) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Cited by 59

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

Adler, L. A., Dirks, B., Deas, P., Raychaudhuri, A., Dauphin, M., Saylor, K., & Weisler, R. (2013) · BMC Psychiatry

Attention Deficit Hyperactivity DisorderSchizophrenia research and treatment

Cited by 45

A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder

Findling, R. L., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Childress, A. C. (2013) · Journal of Child and Adolescent Psychopharmacology

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 40

Emotional Expression During Attention-Deficit/Hyperactivity Disorders Treatment: Initial Assessment of Treatment Effects

Kratochvil, C. J., Faries, D., Vaughan, B., Perwien, A., Busner, J., Saylor, K., Kaplan, S., Buermeyer, C., & Swindle, R. (2007) · Journal of Child and Adolescent Psychopharmacology

Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

Cited by 32

Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder

Childress, A. C., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Findling, R. L. (2014) · Journal of Child and Adolescent Psychopharmacology

Attention Deficit Hyperactivity DisorderPharmacology and Obesity Treatment

Cited by 5